BioGend Therapeutics Co., Ltd. (TPEX:6733)

BioGend Therapeutics Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 18, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	4,896	4,181	4,708	2,247	2,757	3,574
Market Cap Growth	-23.18%	-11.18%	109.50%	-18.50%	-22.86%	46.27%
Enterprise Value	4,351	3,558	3,990	1,720	2,063	3,039
Last Close Price	39.40	33.65	38.25	21.80	26.40	38.34
PS Ratio	25.10	24.94	42.83	71.46	297.47	2565.83
PB Ratio	6.22	4.94	4.92	3.07	2.92	5.07
P/TBV Ratio	7.49	6.09	6.09	4.73	4.53	5.93
EV/Sales Ratio	22.31	21.22	36.30	54.70	222.54	2181.48
Debt / Equity Ratio	0.01	0.01	0.01	0.02	0.01	-
Asset Turnover	0.22	0.17	0.12	0.03	0.01	0.00
Inventory Turnover	3.01	2.29	1.89	1.24	0.64	0.10
Quick Ratio	20.95	21.06	16.90	16.73	28.58	29.27
Current Ratio	21.53	21.60	17.32	17.01	29.24	29.92
Return on Equity (ROE)	-15.13%	-13.30%	-19.07%	-24.54%	-17.51%	-22.51%
Return on Assets (ROA)	-9.04%	-7.78%	-11.79%	-14.85%	-11.74%	-12.53%
Return on Capital (ROIC)	-9.58%	-8.37%	-12.85%	-16.17%	-12.43%	-12.91%
Earnings Yield	-2.60%	-2.79%	-3.32%	-8.21%	-5.02%	-4.07%
FCF Yield	-1.54%	-2.38%	-3.50%	-8.32%	-4.99%	-3.28%
Buyback Yield / Dilution	0.02%	-2.32%	-16.69%	-1.77%	-15.90%	-7.56%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.